Significance of measurable residual disease in adults with secondary acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation

Bone Marrow Transplant. 2022 Nov;57(11):1732-1734. doi: 10.1038/s41409-022-01794-4. Epub 2022 Aug 27.

Eduardo Rodríguez-Arbolí^{1

2}, Corentin Orvain¹, Megan Othus³, Roland B Walter^{4

5

6

7}

¹ Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
² Department of Hematology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CSIC/CIBERONC), University of Seville, Seville, Spain.
³ Public Health Science Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
⁴ Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. rwalter@fredhutch.org.
⁵ Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA. rwalter@fredhutch.org.
⁶ Department of Laboratory Medicine & Pathology, University of Washington, Seattle, WA, USA. rwalter@fredhutch.org.
⁷ Department of Epidemiology, University of Washington, Seattle, WA, USA. rwalter@fredhutch.org.

No abstract available

Publication types